JP2009501208A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501208A5
JP2009501208A5 JP2008520984A JP2008520984A JP2009501208A5 JP 2009501208 A5 JP2009501208 A5 JP 2009501208A5 JP 2008520984 A JP2008520984 A JP 2008520984A JP 2008520984 A JP2008520984 A JP 2008520984A JP 2009501208 A5 JP2009501208 A5 JP 2009501208A5
Authority
JP
Japan
Prior art keywords
stem cells
use according
medicament
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008520984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501208A (ja
Filing date
Publication date
Priority claimed from GBGB0514300.3A external-priority patent/GB0514300D0/en
Application filed filed Critical
Publication of JP2009501208A publication Critical patent/JP2009501208A/ja
Publication of JP2009501208A5 publication Critical patent/JP2009501208A5/ja
Withdrawn legal-status Critical Current

Links

JP2008520984A 2005-07-12 2006-07-12 炎症 Withdrawn JP2009501208A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514300.3A GB0514300D0 (en) 2005-07-12 2005-07-12 Imflammation
PCT/IB2006/002896 WO2007015173A2 (en) 2005-07-12 2006-07-12 Inflammation

Publications (2)

Publication Number Publication Date
JP2009501208A JP2009501208A (ja) 2009-01-15
JP2009501208A5 true JP2009501208A5 (enExample) 2009-08-20

Family

ID=34897117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008520984A Withdrawn JP2009501208A (ja) 2005-07-12 2006-07-12 炎症

Country Status (7)

Country Link
US (1) US20080274089A1 (enExample)
EP (1) EP1904073B1 (enExample)
JP (1) JP2009501208A (enExample)
AU (1) AU2006274653A1 (enExample)
CA (1) CA2614666A1 (enExample)
GB (1) GB0514300D0 (enExample)
WO (1) WO2007015173A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109940D0 (en) 2001-04-23 2001-06-13 Mcgill Tech Ltd Dispensing means
WO2009023795A2 (en) * 2007-08-14 2009-02-19 The Johns Hopkins University Cell-based compositions and method for treating conditions of the nervous system
GB201011589D0 (en) * 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
KR101675123B1 (ko) * 2014-06-27 2016-11-14 연세대학교 산학협력단 Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812027B2 (en) * 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
AU2002230669A1 (en) * 2000-11-06 2002-05-15 The Salk Institute For Biological Studies Postmortem stem cells
EP1480521B1 (en) * 2002-02-15 2015-02-25 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications

Similar Documents

Publication Publication Date Title
Darras et al. Spinal muscular atrophies
Yu et al. New insights into the roles of microglial regulation in brain plasticity-dependent stroke recovery
E. Leonard et al. Inflammation and depression: is there a causal connection with dementia?
Wang et al. Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells
EP4552692A3 (en) Cns gene delivery using peripheral administration of aav vectors
Chen et al. Neural stem cells in the treatment of Alzheimer’s disease: current status, challenges, and future prospects
Skok Mesenchymal stem cells as a potential therapeutic tool to cure cognitive impairment caused by neuroinflammation
Kálmán et al. Human dermal fibroblasts in psychiatry research
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
JP2010518164A5 (enExample)
Hou et al. FGF10 attenuates experimental traumatic brain injury through TLR4/MyD88/NF-κB pathway
NO20054120L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
Zong et al. Molecular mechanisms of exercise intervention in alleviating the symptoms of autism spectrum disorder: Targeting the structural alterations of synapse
JP2009501208A5 (enExample)
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
Srivastava et al. Inhibition of MK2 kinase as a potential therapeutic target to control neuroinflammation in Alzheimer’s disease
Sanchez-Ramos et al. The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review
JP2016523943A5 (enExample)
Liska et al. Granulocyte-colony stimulating factor and umbilical cord blood cell transplantation: synergistic therapies for the treatment of traumatic brain injury
DE602005004026D1 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen
Sharma et al. Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders
Barrow Cell replacement therapy in Parkinson's disease
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
EP4434583A3 (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
Lee et al. THE NEUROPROTECTIVE EFFECT OF THE NOVEL BARBITURATE DERIVATIVE IN A PARKINSON’S DISEASE MOUSE MODEL